Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug- Drug Interactions Clear all
Recruiting Not applicable Interventional

An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.

NCT07373470
View directory record Official record
Conditions
Pharmacogenetics, Depression - Major Depressive Disorder, Pharmacogenomic Drug Interaction, Community Pharmacy Services
Interventions
Comprehensive medication management with PGx testing results, Usual Care
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin

NCT02097953
View directory record Official record
Conditions
Drug Interactions, Pharmacokinetics
Interventions
Daptomycin, Rifampin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 11, 2016 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study of Colchicine With an Oral Contraceptive

NCT01040845
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Norethindrone/Ethinyl Estradiol, Colchicine, Placebo (for Colchicine)
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 4, 2010 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

NCT05505162
View directory record Official record
Conditions
Healthy Female Participants
Interventions
Zibotentan, EE/LNG
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

NCT06250205
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol (COC), Drospirenone / Ethinyl Estradiol (COC)
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

NCT03140527
View directory record Official record
Conditions
Healthy Volunteer, Cystic Fibrosis
Interventions
PTI-801, Placebo, PTI-808
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
33
States / cities
Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants

NCT03928327
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-788, Itraconazole, Rifampin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

NCT02461160
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction With Metformin

NCT00546741
View directory record Official record
Conditions
Healthy Male and Female Subjects
Interventions
Dapagliflozin, Metformin, Dapagliflozin + Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

NCT07216313
View directory record Official record
Conditions
Healthy
Interventions
Denifanstat, Resmetirom
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction - Oral Contraceptive

NCT00399685
View directory record Official record
Conditions
HIV Infections
Interventions
Ortho Tri-Cyclen LO, Ortho Cyclen, Ortho Cyclen + Efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
San Diego, California • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional

A Drug-drug Interaction Study of Avapritinib and Midazolam

NCT04908176
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors
Interventions
Avapritinib, midazolam
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Jacksonville, Florida • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 23, 2026, 3:20 AM EDT
Not listed No phase listed Observational

Bictegravir in the Elderly Living With HIV (BICEP)

NCT05064020
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

NCT06945276
View directory record Official record
Conditions
COVID-19
Interventions
ALG-097558, Dabigatran, Itraconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

NCT05334108
View directory record Official record
Conditions
Drug Interaction
Interventions
Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate, Cohort 3 Probe Substrate Cocktail
Drug · Combination Product
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Results available

Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine

NCT00796991
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Ipilimumab, Carboplatin, Paclitaxel, Dacarbazine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

NCT05255276
View directory record Official record
Conditions
Healthy Adults
Interventions
Sitravatinib 50 mg, Sitravatinib 100 mg, Itraconazole, Rifampin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants

NCT06345794
View directory record Official record
Conditions
Healthy
Interventions
LY4100511 (DC-853), Itraconazole, Fluconazole, Carbamazepine
Drug
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

ADASUVE-Lorazepam Drug-Drug Interaction

NCT01877642
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lorazepam 1 mg IM, Inhaled loxapine 10 mg, Inhaled Placebo, Placebo IM
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

NCT04887194
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Sitravatinib, Warfarin, Dextromethorphan, Midazolam, Digoxin, Rosuvastatin, Nivolumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Goshen, Indiana • Austin, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 2 Interventional

A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia

NCT01779453
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Placebo, Atorvastatin
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants

NCT04956627
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986166, Itraconazole, Extended Phenytoin Sodium, Gemfibrozil
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

NCT05347979
View directory record Official record
Conditions
Cushing Syndrome, Neoplasms
Interventions
Dabigatran Etexilate, Relacorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 23, 2026, 3:20 AM EDT
Completed Phase 1 Interventional

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

NCT02520752
View directory record Official record
Conditions
cMET-dysregulated Advanced Solid Tumors
Interventions
INC280, Midazolam, Caffeine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 23, 2026, 3:20 AM EDT